CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The RABIOPRED project aims to develop a biomarker assay that predicts patient response to TNF-α inhibitors in Rheumatoid Arthritis. This innovation seeks to enhance clinical decision-making and improve health outcomes for patients by identifying those likely to benefit from treatment, ultimately contributing to cost ef…
The aim of the RABIOPRED project is to take the final steps to bring an innovative set of biomarkers that is able to predict response to treatment with TNF-α inhibitors in Rheumatoid Arthritis (RA) to the market and clinical practice.
Millions of RA patients are treated with TNF-α inhibiting agents, currently one of the main second-line treatment strategies for RA.
These expensive biological RA therapies represent a multibillion market.
However, the TNF-α inhibiting agents are not effective in 3…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Huningue
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
